Total Funding
95
82
Total FundingSeries B raised
Growth Score
9 pts
Heat Score
16 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
3178
Neomorph develops protein degradation therapies targeting diseases not addressed by conventional treatments.
- Benjamin Ebert: Founder
- Scott Armstrong: Founder
About the Company
Neomorph develops protein degradation therapies targeting diseases not addressed by conventional treatments. The company designs molecular strategies that induce proximity between proteins to enable selective degradation through natural cellular pathways. Its work focuses on discovering compounds that can modulate protein function by removing or
altering specific targets within cells. The organization applies computational design, structural biology, and chemical biology to support drug discovery efforts. It advances programs across multiple therapeutic areas where controlled protein degradation may provide new treatment options.
